Baylor College of Medicine

RPC-3201: A Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (H-44098)

Description

Content

RPC-3201: Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.

The purpose of this study is to test the effectiveness of the study drug oral ozanimod as a treatment for moderately to severely active Crohn’s Disease (CD). 

Inclusion / exclusion criteria. You may qualify for this study if:

  1. You are a male or female between the ages of 18 and 75;
  2. You have an established diagnosis of Crohn’s Disease (CD) at least 3 months prior to enrollment;
  3. You are experiencing symptoms of abdominal pain and/or diarrhea; 
  4. Have a history of intolerance, lack of response, loss of response, or inadequate response to previous medications such as corticosteroids (e.g, prednisone, budesonide), immunosuppressants (e.g. MTX, 6-MP, azathioprine), and biologics (e.g. Humira, Entyvio, Remicade, Simponi)

Contact

Nimrah Saleem

Phone 1: 713–798–7616

IRB: H-44098

Status:

Active

Created:

Back to topback-to-top